GlassScriptPhysician profile
Nicholas Wiemer
NPI 1073019519
$9,233.20
in general payments reported to CMS, 2019-2025
38 companies · $3,559 in 2025
The $3,559 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2022: $514 · 2023: $1,694 · 2024: $3,355 · 2025: $3,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,705 · Education: $478 · Consulting Fee: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,705.11 |
| Education | $477.96 |
| Consulting Fee | $425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,556.88 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,518.80 | 2022-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,315.46 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Glaxosmithkline, LLC. | $742.44 | 2022-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $651.24 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $531.78 | 2022-2025 | Saphnelo |
| Ucb, INC. | $481.80 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $293.48 | 2024-2025 | Orencia |
| Sobi, INC | $260.87 | 2023-2025 | |
| Abbott Laboratories | $194.63 | 2024-2025 | Freestyle Libre 3 |
| Ani Pharmaceuticals, INC. | $155.32 | 2024 | Purified Cortrophin Gel |
| Cequr Corporation | $148.62 | 2024-2025 | Cequr Simplicity |
| Genentech USA, INC. | $141.75 | 2019-2025 | Actemra |
| Fresenius Kabi USA, LLC | $125.50 | 2023-2025 | Idacio |
| Lilly USA, LLC | $123.28 | 2023-2025 | Mounjaro, Taltz, Zepbound |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $114.73 | 2023-2024 | Lupkynis |
| Pfizer INC. | $109.20 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $92.13 | 2024-2025 | Yorvipath |
| Sandoz INC. | $82.89 | 2023-2024 | Hyrimoz |
| Genzyme Corporation | $78.69 | 2024-2025 | |
| Novo Nordisk INC | $61.08 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Alexion Pharmaceuticals, INC. | $51.90 | 2023-2025 | Strensiq |
| Janssen Scientific Affairs, LLC | $38.79 | 2025 | Tremfya |
| Antares Pharma, INC. | $35.29 | 2024-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $33.06 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.01 | 2024 | Cyltezo |
| Halozyme INC | $31.10 | 2023 | |
| Organon LLC | $28.65 | 2024-2025 | Hadlima, Renflexis |
| Corcept Therapeutics | $28.22 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $25.16 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $23.32 | 2024 | Arcalyst |
| Sequel Med Tech, LLC | $21.75 | 2025 | Twiist |
| Radius Health, INC. | $20.58 | 2023 | Tymlos |
| Insulet Corporation | $18.42 | 2025 | Omnipod |
| Tandem Diabetes Care, INC. | $18.07 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Almatica Pharma LLC | $15.31 | 2024 | Loreev Xr |
| Dexcom, INC. | $15.16 | 2023 | Dexcom G6 Transmitter |
| Kiniksa Pharmaceuticals, LTD. | $14.84 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Wiemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.